Критерии оценки когнитивных нарушений в клинических исследованиях
Аннотация
Об авторах
А. П. Соловьева
ФГБУ "Научный центр экспертизы средств медицинского применения" Минздрава России
Россия
Россия
главный эксперт управления № 2 по эффективности и безопасности лекарственных средств Центра экспертизы и контроля готовых лекарственных средств
Петровский б-р, д. 8, стр. 2, Москва, 127051, Российская Федерация
Д. В. Горячев
ФГБУ "Научный центр экспертизы средств медицинского применения" Минздрава России
Россия
Россия
д-р мед. наук, директор Центра экспертизы и контроля готовых лекарственных средств
Петровский б-р, д. 8, стр. 2, Москва, 127051, Российская Федерация
В. В. Архипов
ФГБУ "Научный центр экспертизы средств медицинского применения" Минздрава России
Россия
Россия
д-р мед. наук, проф., начальник отдела взаимодействия лекарственных средств и рациональной фармакотерапии
Петровский б-р, д. 8, стр. 2, Москва, 127051, Российская Федерация
Список литературы
1. Олефир ЮВ. Результаты проведенного анализа и обобщения материалов по безопасности клинических исследований. Безопасность и риск фармакотерапии. 2017;(1):5–10. [Olefir YuV. The results of the analysis of materials on the safety of clinical trials. Bezopasnost i risk farmakoterapii=Safety and Risk of Pharmacotherapy. 2017;(1):5–10 (In Russ.)]
2. Горячев ДВ, Тельных МЮ, Бунятян НД. Регуляторные подходы к оценке биоаналогов для лечения ревматических заболеваний. Ведомости Научного центра экспертизы средств медицинского применения. 2017;(3):155–63. [Goryachev DV, Telnykh MYu, Bunyatyan ND. Regulatory approaches to evaluation of biosimilars for treatment of rheumatic diseases. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya=Тhе Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2017;(3):155–63 (In Russ.)]
3. Захаров ВВ. Когнитивные нарушения в неврологической практике. Трудный пациент. 2005;3(5):4–9. [Zakharov VV. Cognitive disorders in neurological practice. Trudny patsient=Difficult Patient. 2005;3(5):4–9 (In Russ.)]
4. Дамулин ИВ. Сосудистая деменция: некоторые патогенетические, диагностические и терапевтические аспекты. Русский медицинский журнал. 2008;16(5):253–8. [Damulin IV. Vascular dementia: some pathogenetic, diagnostic and therapeutic aspects. Russkiy meditsinskiy zhurnal=Russian Medical Journal. 2008;16(5):253–8 (In Russ.)]
5. Larrabee GJ, Crook TH. Estimated prevalence of age-associated memory impairment derived from standardized tests of memory function. Int Psychogeriatr. 1994;6(1):95–104.
6. Lezak MD, Howieson DB, Bigler ED, Tranel D. Neuropsychological assessment. 5th ed. New York; Oxford University Press: 2012.
7. Carson N, Leach L, Murphy KJ. A re-examination of Montreal Cognitive Assessment (MoCA) cutoff scores. Int J Geriatr Psychiatry. 2018;33(2):379–88. https://doi.org/10.1002/gps.4756
8. Kessels RPC, Brands AMA. Neuropsychological assessment. In: Biessels GJ, Luchsinger JA, eds. Diabetes and the Brain. Totowa, NJ: Humana Press; 2009. P. 77−102.
9. Vincent AS, Roebuck-Spencer TM, Fuenzalida E, Gilliland K. Test-retest reliability and practice effects for the ANAM General Neuropsychological Screening battery. Clin Neuropsychol. 2017;32(3):479–94. https://doi.org/10.1080/13854046.2017.1368716
10. Webber TA, Soble JR. Utility of various WAIS-IV Digit Span indices for identifying noncredible performance validity among cognitively impaired and unimpaired examinees. Clin Neuropsychol. 2018;32(4):657–70. https://doi.org/10.1080/13854046.2017.1415374
11. Mitrushina MN, Boone KB, Razani J, D’Elia LF. Handbook of normative data for neuropsychological assessment. New York: Oxford University Press; 2005.
12. Vanderploeg RD, ed. Clinician’s guide to neuropsychological assessment. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 2000.
13. Folstein MF, Folstein SE, McHugh PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.
14. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Neurology. 2001;56(9):1133–42.
15. Tsoi KK, Chan JY, Hirai HW, Wong SY, Kwok TC. Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(9):1450–8. https://doi.org/10.1001/jamainternmed.2015.2152
16. Lin JS, O’Connor E, Rossom RC, Perdue LA, Burda BU, Thompson M, et al. Screening for cognitive impairment in older adults: an evidence update for the U.S. Preventive Services Task Force. Report No. 14-05198-EF-1. Rockville (MD); 2013
17. Stein J, Luppa M, Maier W, Tebarth F, Heser K, Scherer M, et al. The assessment of changes in cognitive functioning in the elderly: age- and education-specific reliable change indices for the SIDAM. Dement Geriatr Cogn Disord. 2012;33(2–3):73–83. https://doi.org/10.1159/000336864
18. Stein J, Luppa M, Maier W, Wagner M, Wolfsgruber S, Scherer M, et al. Assessing cognitive changes in the elderly: reliable change indices for the Mini-Mental State Examination. Acta Psychiatr Scand. 2012;126(3):208–18. https://doi.org/10.1111/j.1600-0447.2012.01850.x
19. Stein J, Luppa M, Luck T, Maier W, Wagner M, Daerr M, et al. The assessment of changes in cognitive functioning: age-, education-, and gender-specific reliable change indices for older adults tested on the CERAD-NP battery: results of the German Study on Ageing, Cognition, and Dementia in Primary Care Patients (AgeCoDe). Am J Geriatr Psychiatry. 2012;20(1):84–97. https://doi.org/10.1097/JGP.0b013e318209dd08
20. Skinner J, Carvalho JO, Potter GG, Thames A, Zelinski E,Crane PK et al. The Alzheimer´s Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. Brain Imaging Behav. 2012;6(4):489–501. https://doi.org/10.1007/s11682-012-9166-3
21. Karin A, Hannesdottir K, Jaeger J, Annas P, Segerdahl M, Karlsson P, et al. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response. Acta Neurol Scand. 2014;129(2):114–22. https://doi.org/10.1111/ane.12153
22. Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–63. https://doi.org/10.1016/S0140-6736(15)60461-5
23. Cedarbaum JM, Jaros M, Hernandez C, Coley N, Andrieu S, Grundman M, et al. Rationale for use of the Clinical Dementia Rating Sum of Boxes as primary outcome measure for Alzheimer’s disease clinical trials. Alzheimers Dement. 2013;9(1 Suppl):45–55. https://doi.org/10.1016/j.jalz.2011.11.002
24. Wessels AM, Dowsett SA, Sims JR. Detecting treatment group differences in Alzheimer’s disease clinical trials: a comparison of Alzheimer’s disease Assessment Scale – Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating – Sum of Boxes (CDR-SB). J Prev Alzheimers Dis. 2018;5(1):15–20. https://doi.org/10.14283/jpad.2018.2
25. Langbaum JB, Hendrix SB, Ayutyanont N, Chen K, Fleisher AS, Shah RC, et al. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10(6):666–74. https://doi.org/10.1016/j.jalz.2014.02.002
26. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–72. https://doi.org/10.1212/01.wnl.0000187889.17253.b1
27. Mormile MEE, Langdon JL, Hunt TN. The role of gender in neuropsychological assessment in healthy adolescents. J Sport Rehabil. 2018;27(1):16–21. https://doi.org/10.1123/jsr.2016-0140
28. Plourde V, Hrabok M, Sherman EMS, Brooks BL. Validity of a computerized cognitive battery in children and adolescents with neurological diagnoses. Arch Clin Neuropsychol. 2018;33(2):247–53. https://doi.org/10.1093/arclin/acx067
Рецензия
Для цитирования:
Соловьева А.П., Горячев Д.В., Архипов В.В. Критерии оценки когнитивных нарушений в клинических исследованиях. Ведомости Научного центра экспертизы средств медицинского применения. 2018;8(4):218-230. https://doi.org/10.30895/1991-2919-2018-8-4-218-230
For citation:
Solovyova A.P., Goryachev D.V., Arkhipov V.V. Criteria for Assessment of Cognitive Impairment in Clinical Trials. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2018;8(4):218-230. (In Russ.) https://doi.org/10.30895/1991-2919-2018-8-4-218-230
Просмотров: 3629
Послать статью по эл. почте 